Review
Oncology
Zhiying Shao, Xin Liu, Chanjuan Peng, Liping Wang, Dong Xu
Summary: Combining portal vein embolization with transcatheter arterial chemoembolization may bring breakthroughs in treating hepatocellular carcinoma. Various studies have explored the feasibility, efficacy, long-term survival benefits, and potential side effects of this combined treatment approach.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Yiwen Qiu, Yi Yang, Tao Wang, Shu Shen, Wentao Wang
Summary: This study investigated the impact of microscopic portal vein invasion (MPVI) on the efficacy of postoperative adjuvant transcatheter arterial chemoembolization (PA-TACE). The results showed that PA-TACE had better recurrence-free survival (RFS) and overall survival (OS) outcomes in patients without MPVI. However, for patients with MPVI, PA-TACE did not significantly improve RFS or OS outcomes.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Chengjian He, Naijian Ge, Xiangdong Wang, Hai Li, Shiguang Chen, Yefa Yang
Summary: This study evaluated the safety and efficacy of conversion therapy with portal vein embolization (PVE) and transcatheter arterial chemoembolization (TACE) in patients with large unresectable hepatocellular carcinoma (HCC) and ipsilateral portal vein tumor thrombus (PVTT). The results showed that PVE + TACE treatment prolonged overall survival and conferred more favorable outcomes compared to treatment with tyrosine kinase inhibitors (TKIs) + TACE.
FRONTIERS IN ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Xiao-fei Zhang, Lin Lai, Hui Zhou, Yuan-jun Mo, Xu-quan Lu, Min Liu, Yun-xin Lu, En-cun Hou
Summary: This meta-analysis suggests that SBRT plus TACE is superior to monotherapy in treating HCC with PVTT, as it improves survival rates and treatment response without significant increase in adverse events.
Article
Oncology
Yangxun Pan, Jie Mei, Jinbin Chen, Deyao Zhang, Juncheng Wang, Xiaohui Wang, Minjiang Yi, Zhongguo Zhou, Yaojun Zhang, Minshan Chen, Rongping Guo, Li Xu
Summary: This study aimed to investigate the survival associations of adjuvant portal vein perfusion chemotherapy (PVC) and neoadjuvant hepatic arterial infusion chemotherapy (HAIC) in patients with resectable BCLC stage B/C HCC. The results showed that compared with adjuvant PVC, patients treated with neoadjuvant HAIC had better survival outcomes and lower recurrence rates.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Medicine, General & Internal
Shou-Wu Lee, Chieh-Ling Yen, Yu-Chi Cheng, Sheng Shun Yang, Teng-Yu Lee
Summary: Transcatheter arterial chemoembolization (TACE) is the recommended treatment for intermediate stage hepatocellular carcinoma (HCC). This study aimed to determine the radiological characteristics associated with prognosis in patients with intermediate stage HCC receiving TACE. The results showed that complete lipiodol retention, tumor feeding artery blockage, and no residual tumor blush were significant factors correlated with achieving objective response (OR) in TACE. Patients with OR had better overall survival than those without.
Article
Multidisciplinary Sciences
Chonlakiet Khorprasert, Kanokphorn Thonglert, Petch Alisanant, Napapat Amornwichet
Summary: For individuals with HCC and PVTT in Thailand, limited treatment options are available due to disease extent, poor liver function, and lack of coverage for immuno/targeted therapy. Radiotherapy has become increasingly important in these patients and is considered a safe and effective therapeutic option, with overall survival being closely related to factors such as patient age, tumor size, radiation dose, and tumor/PVTT response. Further research is necessary to validate these findings through prospective randomized trials.
Article
Plant Sciences
He Zhu, Si-Yu Wang, Jin-Hao Zhu, Hui Liu, Ming Kong, Qian Mao, Wei Zhang, Song-Lin Li
Summary: The study showed that combining ginsenosides can continuously improve the efficacy and safety of TACE in the treatment of HCC, with Rg3 being the preferred choice for combination therapy.
Article
Gastroenterology & Hepatology
Lei Guo, Xubiao Wei, Shuang Feng, Jian Zhai, Weixing Guo, Jie Shi, Wan Yee Lau, Yan Meng, Shuqun Cheng
Summary: This study compared the outcomes of radiotherapy (RT) prior to transcatheter arterial chemoembolization (TACE) with TACE followed by RT in patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT). The results showed that RT + TACE group had better overall survival (OS) and progression-free survival (PFS) compared to TACE + RT group, especially for patients with PVTT type III/IV. Therefore, applying RT prior to TACE may be a more effective treatment strategy for these patients.
HEPATOLOGY INTERNATIONAL
(2022)
Article
Oncology
Yun Huang, Zeyu Zhang, Weijun Liao, Kuan Hu, Zhiming Wang
Summary: The study showed that combination therapy with sorafenib, camrelizumab, TACE, and SBRT is an effective downstaging strategy for advanced HCC with PVTT, resulting in good treatment responses and survival outcomes with few adverse events.
FRONTIERS IN ONCOLOGY
(2021)
Article
Gastroenterology & Hepatology
Ke Su, Tao Gu, Ke Xu, Jing Wang, Hongfei Liao, Xueting Li, Lianbin Wen, Yanqiong Song, Jiaqi Zhong, Bingsheng He, Xin Liu, Jie He, Yanlin Liu, Qi Li, Xunjie Feng, Siyu Chen, Binbin Yang, Weihong Huang, Hongping Jin, Xiaotong Luo, Teng Hu, Jiali Chen, Zhenying Wu, Simin Lu, Jianwen Zhang, Mingyue Rao, Yunchuan Xie, Xiaoning Zhu, Lan Chen, Bo Li, Song Su, Xiaoli Yang, Juan Wang, Hao Zeng, Pan Wang, Min Yan, Xiaojing Chen, Kun He, Yunwei Han
Summary: This retrospective study compared the efficacy of Gamma knife radiosurgery (GKR) and transcatheter arterial chemoembolization (TACE) in the treatment of hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT). The study found that GKR was associated with better overall survival (OS) in PVTT II-IV patients compared to TACE, while the two treatments had comparable OS in PVTT I patients.
HEPATOLOGY INTERNATIONAL
(2022)
Article
Oncology
Sang-Hoon Kim, Deok-Bog Moon, Yo-Han Park, Sung-Gyu Lee, Ki-Hun Kim, Shin Hwang, Chul-Soo Ahn, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Minjae Kim, Byeong-Gon Na, Geunhyeok Yang, Sung Min Kim, Rak-kyun Oh
Summary: This study aimed to investigate the prognostic factors associated with recurrence and survival in hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). The study included 161 HCC patients with PVTT who underwent hepatectomy. Regression analyses showed that absence of esophageal varices, maximal tumor size <5 cm, tumor location in a single lobe, and anatomical resection were favorable prognostic factors for overall survival and R0 resection, while absence of microvascular invasion was a favorable prognostic factor for recurrence-free survival. Aggressive management was required for recurrent HCC to prolong overall survival.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Zhiqiang Wu, Jian Gao, Wenquan Zhuang, Jianyong Yang, Wenbo Guo
Summary: This study evaluated the efficacy and safety of TACE combined with HAIC in HCC patients complicated with PVTT. The results showed that compared to TACE alone, TACE combined with HAIC may be safer and provide more benefits in terms of improving overall survival in HCC patients with PVTT in the trunk.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
(2022)
Article
Oncology
Sihang Cheng, Xiang Yu, Siyun Liu, Zhengyu Jin, Huadan Xue, Zhiwei Wang, Ping Xie
Summary: A prognostic nomogram was developed and validated for eastern patients with HBV-associated HCC and PVTT undergoing DEBTACE treatment. The nomogram accurately predicted 6-, 12-, and 18-month overall survival based on factors including tumor number, GGT level, and PVTT level. Performance evaluation of the nomogram demonstrated its excellent performance in both training and test cohorts.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Oncology
Chao An, Mengxuan Zuo, Wang Li, Qifeng Chen, Peihong Wu
Summary: This study compared the effectiveness of hepatic arterial infusion chemotherapy (HAIC) and transarterial chemoembolization (TACE) in patients with infiltrative hepatocellular carcinoma (HCC) and found that HAIC significantly improved overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) compared to TACE. A nomogram model including various factors showed good predictive accuracy and outperformed other staging systems and conventional indices.
FRONTIERS IN ONCOLOGY
(2021)